Clinically stable treatment-experienced adults receiving tenofovir and didanosine

被引：3

作者：

Di Biagio, A

Beltrame, A

Cenderello, G

Ferrea, G

De Maria, A

机构：

[1] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy

[2] Univ Genoa, Dept Infect Dis, Genoa, Italy

[3] ASL1 Imperiese, Dept Infect Dis, San Remo, Italy

[4] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy

来源：

HIV CLINICAL TRIALS | 2006年 / 7卷 / 01期

关键词：

drug-experienced; HIV-1; tenofovir;

D O I：

10.1310/0B0R-J1LP-KQPF-43HB

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Method: Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddl) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddl plus lamivudine and to 19 patients on ddl plus stavudine. Results: Patients treated with TDF and ddl do not have a higher risk of early immunological or virological failure. Conclusion: Treatment success and increase in CD4+ lymphocytes may depend, among other factors, on historical CD4+ nadir. These data agree with previous work and argue against preemptive switches for fear of side effects or immunological/virological failure away from a successful ddl-TDF combination in clinically stable drug-experienced patients.

引用

收藏

页码：10 / 15

页数：6

相关论文

共 14 条

[1] Pharmacologic perspectives for once-daily antiretroviral therapy [J].

Anderson, PL .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) :1924-1934

[2] Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine [J].

Barrios, A ;

Rendón, A ;

Negredo, E ;

Barreiro, P ;

Garcia-Benayas, T ;

Labarga, P ;

Santos, J ;

Domingo, P ;

Sánchez-Conde, M ;

Maida, I ;

Martín-Carbonero, L ;

Núñez, M ;

Blanco, F ;

Clotet, B ;

Sambeat, MA ;

Gil, P ;

Gonzalez-Lahoz, J ;

Cooper, D ;

Soriano, V .

AIDS, 2005, 19 (06) :569-575

[3] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].

Gallant, JE ;

Staszewski, S ;

Pozniak, AL ;

DeJesus, E ;

Suleiman, JMAH ;

Miller, MD ;

Coakley, DF ;

Lu, B ;

Toole, JJ ;

Cheng, AK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201

[4] Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus [J].

Karras, A ;

Lafaurie, M ;

Furco, A ;

Bourgarit, A ;

Droz, D ;

Sereni, D ;

Legendre, C ;

Martinez, F ;

Molina, JM .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1070-1073

[5] Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir [J].

Karrer, U ;

Ledergerber, B ;

Furrer, H ;

Elzi, L ;

Battegay, M ;

Cavassini, M ;

Gayet-Ageron, A ;

Hirschel, B ;

Schmid, P ;

Russotti, M ;

Weber, R ;

Speck, RF .

AIDS, 2005, 19 (17) :1987-1994

[6]

KEARNEY BP, 2003, 10 C RETR OPP INF FE

[7] Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine [J].

León, A ;

Martinez, E ;

Mallolas, J ;

Laguno, M ;

Blanco, JL ;

Pumarola, T ;

Gatell, JM .

AIDS, 2005, 19 (02) :213-215

[8] Tenofovir disoproxil fumarate - A review of its use in the management of HIV infection [J].

Lyseng-Williamson, KA ;

Reynolds, NA ;

Plosker, GL .

DRUGS, 2005, 65 (03) :413-432

[9]

Maggiolo Franco, 2002, HIV Clin Trials, V3, P371, DOI 10.1310/98B3-PWG8-PMYW-W5BP

[10] Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults [J].

Martínez, E ;

Milinkovic, A ;

de Lazzari, E ;

Ravasi, G ;

Blanco, JL ;

Larrousse, M ;

Mallolas, J ;

García, F ;

Miró, JM ;

Gatell, JM .

LANCET, 2004, 364 (9428) :65-67